Thermo Fisher Scientific Inc. $TMO Shares Sold by Peoples Financial Services CORP.

Key Points

• Peoples Financial Services CORP. reduced its stake in Thermo Fisher Scientific by 48.7% during the second quarter, holding 576 shares valued at $234,000.
• Thermo Fisher Scientific's earnings per share for the last quarter were reported at $5.36, surpassing analyst expectations of $5.22.
• The company recently declared a $0.43 quarterly dividend, with a payout ratio currently at 9.95%, to be distributed on October 15th.

Peoples Financial Services CORP. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 48.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 576 shares of the medical research company's stock after selling 547 shares during the quarter. Peoples Financial Services CORP.'s holdings in Thermo Fisher Scientific were worth $234,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of TMO. CBIZ Investment Advisory Services LLC increased its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $31,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last quarter. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Up 1.1%

Shares of TMO stock opened at $464.18 on Monday. The stock's fifty day moving average is $476.70 and its two-hundred day moving average is $447.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market capitalization of $175.28 billion, a P/E ratio of 26.85, a PEG ratio of 2.52 and a beta of 0.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a report on Friday, July 11th. HSBC reaffirmed a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating on the stock. Finally, UBS Group boosted their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.